Drug · CHEMBL1663
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group I (Perflutren Protein-type A Microspheres, CEUS) vs Group II (Standard of Care): deaths from any cause | 0 of 52 | 0 of 52 | 104 | NCT03199274 | Trial comparisons |
| Group I (Perflutren Protein-type A Microspheres, CEUS) vs Group II (Standard of Care): serious adverse events | 0 of 52 | 0 of 52 | 104 | NCT03199274 | Trial comparisons |
| For Cause vs Surveillance: Abnormal Biopsy | 10 of 20 | 7 of 20 | 40 | NCT02625428 | Trial comparisons |
| For Cause vs Surveillance: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT02625428 | Trial comparisons |
| For Cause vs Surveillance: serious adverse events | 2 of 20 | 1 of 20 | 40 | NCT02625428 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: deaths from any cause | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 4 of 8 | 9 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: Number of Participants With Clinically Significant Abnormality in Physical Examination Findings | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: serious adverse events | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Low Pulmonary Arterial Pressure vs Elevated Pulmonary Arterial Pressure: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT00918866 | Trial comparisons |
| Optison Product First Followed by Placebo Control (5%Dextrose) vs Placebo Control (5% Dextrose) First Followed by the Optison: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT00878878 | Trial comparisons |
| Acoustic Angiography vs Image Optimization: deaths from any cause | 0 of 3 | 0 of 15 | 18 | NCT03544268 | Trial comparisons |
| Acoustic Angiography vs Image Optimization: serious adverse events | 0 of 3 | 0 of 15 | 18 | NCT03544268 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1663/comparisons